Skip to content

    Honasa Consumer Q1 FY27 earnings call

    HONASA
    Fast Moving Consumer Goods·13 Aug 2026
    Management Summary

    Honasa Consumer Limited reported a strong Q1 FY27, achieving 32% revenue growth and significant EBITDA expansion driven by operating leverage and core brand momentum. Mamaearth and younger brands demonstrated robust performance, while the company strategically entered the fragrance category with its new FIKN brand. Despite inflationary pressures, management is confident in its distribution health and long-term margin expansion targets.

    Highlights

    10

    • Revenue grew 32% YoY, demonstrating strong market demand and execution.

    • Volume growth of 30.5% indicates healthy underlying business expansion, not just price-led growth.

    • EBITDA of almost INR110 crores and PAT of INR90 crores reflect robust profitability and operational efficiency.

    • Significant EBITDA profile improvement driven by operating leverage (300-350 bps) and seasonality (50 bps).

    • Strong cash generation of INR83 crores, maintaining negative working capital.

    • Mamaearth accelerated to high teens growth, with key products like Rice face wash and Rosemary shampoo (INR100 crores+ ARR) performing well.

    • Younger brands (Aqualogica, Dr. Sheth's, BBlunt, Staze, Reginald) continue strong growth at 40%+.

    • BTM Ventures, acquired in January, reached INR150 crores ARR, growing almost 100% and expanding its franchise.

    • Successful entry into the fragrance category with the new FIKN brand, leveraging internal R&D for long-stay perfumes.

    • Robust distribution expansion with 40%+ secondary sales growth in GT and MT, and 20%+ growth in e-commerce.

    Concerns

    2

    • Input cost inflation (crude oil, packaging materials) is noted, with price increases implemented towards the end of Q1 to offset Q2 impact, indicating potential margin pressure if not managed effectively.

    • Fluence Pharma acquisition is still in the 'condition precedent process', delaying full integration and contribution to the nutraceuticals business.

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue Growth32%+32%YoY
    2. 02Volume Growth30.5%+30.5%YoY
    3. 03EBITDA₹110 Cr
    4. 04PAT₹90 Cr
    5. 05Cash Generated₹83 Cr

    Capital allocation

    4
    high confidence
    CategoryHeadline
    M&A

    BTM Ventures

    acquisition · integrated

    M&A

    FIKN (new brand)

    Other · Other

    M&A

    Fluence Pharma

    acquisition · pending regulatory

    Liquidity

    Cash ₹83 crores

    Generated INR83 crores of cash this quarter, maintaining negative working capital.

    Guidance & targets

    8
    CategoryTargetPriority
    Margin
    EBITDA Margin Expansion
    100-150 basis points each year
    		High
    Margin
    Target EBITDA Margin
    15%
    		High
    Revenue
    Younger Brands Growth
    40% plus
    		High
    Revenue
    Rice Franchise Size
    INR500 crores
    		Medium
    Revenue
    Rosemary Shampoo Franchise Size
    INR250 crores
    		Medium
    Revenue
    Mamaearth Moisturizers ARR
    INR50 crores
    		Medium
    Revenue
    Mamaearth Sunscreens ARR
    INR100 crores
    		Medium
    Revenue
    Mamaearth Acne/Dandruff Partitions ARR
    INR100 crores
    		Medium

    What to watch in Q2 FY27

    5

    Fluence Pharma Acquisition Status

    next quarter
    CurrentStill in condition precedent and diligence process
    TargetCompleted / Integrated

    Why it matters

    Successful integration is key for building the nutraceuticals business and realizing its growth potential.

    I mean, fluence is one proposition that we announced where we're still in the condition precedent process and the diligence process, which is getting completed. As it completes is when we will be able to talk about it getting integrated.

    Risks & concerns

    1
    RiskSeverity

    Input Cost Inflation

    Crude oil and packaging material prices are on an inflationary trend due to West Asia war, with Q2 expected to see the real impact, though mitigated by Q1 inventory management and calibrated price increases. — Management acknowledged

    medium

    Q&A highlights

    8

    “Hey, Vivek., like we have said, from a five-year view, we have a high-teens agenda. We will make sure that we deliver that CAGR over the next five years. If you divide that over years, there will be years where we will do better than that in terms of our overall growth profile. And there will be years where we will be just about that CAGR in terms of our growth profile. And I think this is going to be an year where we will be better than that CAGR on the growth profile.”

    Analyst sought clarity on growth trajectory given increasing base, management reiterated long-term CAGR and expressed confidence for better performance this year.

    asked by Vivek M

    2 min read7 chapters

    Detailed Narrative

    01

    Strong Q1 FY27 Performance and Profitability

    Honasa Consumer Limited delivered a robust Q1 FY27, achieving 32% revenue growth and 30.5% volume growth. The company reported an EBITDA of almost INR110 crores and a PAT of INR90 crores, alongside generating INR83 crores of cash. This performance reflects a significant improvement in the EBITDA profile compared to the previous year, driven by operating leverage and seasonal benefits.

    02

    Strategic Entry into Fragrance Category with FIKN

    Honasa has strategically entered the high-growth fragrance category with the launch of its new brand, FIKN. This brand is positioned as India's first elixir-based perfume, clinically tested for 12 hours long-stay, addressing a key consumer need. This launch follows two years of internal R&D and product capability building, learning from a previous attempt with Mamaearth, and recognizing the category's low penetration in India (3% vs 11% globally).

    03

    Mamaearth's Accelerated Growth and Product Performance

    The core brand, Mamaearth, accelerated to high teens growth in Q1 FY27, fueled by focus categories and hero SKUs. Rice face wash has become the number one product, while Ubtan and Rosemary shampoo (now an INR100 crores+ ARR ingredient) also demonstrated strong double-digit growth. Additionally, sun care products for Mamaearth performed very strongly during the season.

    04

    Momentum in Younger Brands and Inorganic Growth

    Honasa's portfolio of younger brands, including Aqualogica, Dr. Sheth's, BBlunt, Staze, and Reginald, collectively achieved strong growth exceeding 40% plus. BTM Ventures, acquired in January, has shown remarkable progress, reaching an ARR of INR150 crores in the last quarter and growing almost 100% since its acquisition, validating the company's inorganic growth model.

    05

    Distribution Expansion and Channel Strength

    The company reported robust distribution expansion, with secondary sales growth of over 40% in general trade and modern trade. Modern trade offtakes also grew over 40%. E-commerce channels contributed over 20% growth, with a strong focus on quick commerce and expanding reach in Tier 2 and beyond markets. The distribution system is healthy, with inventory levels maintained at less than 30 days.

    06

    Commitment to Long-Term EBITDA Margin Expansion

    Honasa reiterated its commitment to expanding EBITDA margin by 100-150 basis points annually over the next five years, targeting a 15% margin. Q1 FY27 saw significant operating leverage of 300-350 basis points, partly due to mix impact and operating efficiencies, along with a 50 basis points benefit from seasonality in high-margin categories like face wash and sunscreen.

    07

    Future Growth Drivers and Product Pipeline

    Beyond current successes, Honasa is cultivating new growth drivers. The Rice franchise is projected to become an INR500 crores franchise, and Rosemary shampoo is targeted for INR250 crores next year. Mamaearth's moisturizers are nearing INR50 crores ARR, and sunscreens are expected to become an INR100 crores piece. New product partitions in acne (Tea Tree Face Wash) and dandruff (Lemon & Aloe Shampoo) are also anticipated to reach INR100 crores ARR within 2-3 years.

    This is an AI-generated summary of a publicly available earnings call transcript.